The mGlu2/3 Receptor Agonists LY354740 and LY379268 Differentially Regulate Restraint-Stress-Induced Expression of c-Fos in Rat Cerebral Cortex

Neuroscience Journal
M M MenezesK A Svensson

Abstract

Metabotropic glutamate 2/3 (mGlu2/3) receptors have emerged as potential therapeutic targets due to the ability of mGlu2/3 receptor agonists to modulate excitatory transmission at specific synapses. LY354740 and LY379268 are selective and potent mGlu2/3 receptor agonists that show both anxiolytic- and antipsychotic-like effects in animal models. We compared the efficacy of LY354740 and LY379268 in attenuating restraint-stress-induced expression of the immediate early gene c-Fos in the rat prelimbic (PrL) and infralimbic (IL) cortex. LY354740 (10 and 30 mg/kg, i.p.) showed statistically significant and dose-related attenuation of stress-induced increase in c-Fos expression, in the rat cortex. By contrast, LY379268 had no effect on restraint-stress-induced c-Fos upregulation (0.3-10 mg/kg, i.p.). Because both compounds inhibit serotonin 2A receptor (5-HT2AR)-induced c-Fos expression, we hypothesize that LY354740 and LY379268 have different in vivo properties and that 5-HT2AR activation and restraint stress induce c-Fos through distinct mechanisms.

References

Nov 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S C HeinrichsG F Koob
Dec 13, 1993·Neuroreport·R A LeslieD G Grahame-Smith
Jan 1, 1997·Annual Review of Pharmacology and Toxicology·P J Conn, J P Pin
Feb 12, 1999·Brain Research. Brain Research Reviews·R Anwyl
Oct 26, 1999·Neuropharmacology·D D SchoeppJ A Monn
Oct 26, 1999·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·A G LamJ McCulloch
Aug 11, 2000·Journal of Neurochemistry·J Cartmell, D D Schoepp
Oct 12, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J C Gewirtz, G J Marek
Jul 16, 2002·Pharmacology, Biochemistry, and Behavior·Aleksandra KłodzinskaAndrzej Pilc
Jan 25, 2005·Nature Reviews. Drug Discovery·Chad J SwansonDarryle D Schoepp
Feb 17, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Magda Alves de MedeirosLuiz Eugênio Mello
Feb 24, 2006·European Journal of Pharmacology·Takeshi IzumiTsukasa Koyama
Jun 27, 2006·Neuroscience Letters·Jens D Mikkelsen, Marianne H Larsen
Jul 29, 2006·Science·Noelia V WeisstaubJay A Gingrich
May 31, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jean-Claude BéïqueRodrigo Andrade
Aug 23, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eduardo DunayevichGary D Tollefson
Sep 6, 2007·Proceedings of the National Academy of Sciences of the United States of America·Lucila KargiemanFrancesc Artigas
Feb 26, 2008·Nature·Javier González-MaesoStuart C Sealfon
Apr 8, 2010·European Journal of Pharmacology·Gerard J Marek

❮ Previous
Next ❯

Software Mentioned

MCID Elite
GraphPad Prism

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here